Magnasense Press Releace

Investors

Contact

For questions related to Investor Relations, please contact:

Email: ir@subgen.ai

2024-05-29 08:30 AegirBios VD Marco Witteveen deltar i SalivaDirects 3:e årliga konferens i Washington, DC, 5-7 juni 2024
2024-05-29 08:30 AegirBio’s CEO Marco Witteveen to Attend SalivaDirect's 3rd Annual Conference in Washington, DC, June 5-7, 2024
2024-05-28 22:21 Kallelse till årsstämma i AegirBio AB (publ)
2024-05-21 08:30 AEGIRBIO AB SUCCESSFULLY COMPLETES AN ADDITIONAL MILESTONE OF RADx® TECH PROGRAM
2024-05-21 08:30 AEGIRBIO AB SLUTFÖR FRAMGÅNGSRIKT YTTERLIGARE EN MILSTOLPE I RADx® TECH-PROGRAMMET
2024-05-17 08:22 AEGIRBIO AVGER DELÅRSRAPPORT OCH REDOGÖR FÖR VÄSENTLIGA HÄNDELSER Regulatory
2024-05-16 08:30 AEGIRBIO study published in Multiple Sclerosis and Related Disorders journal
PreviousNext

Contact

For questions related to Investor Relations, please contact:

Email: ir@subgen.ai

Subscribe to our press releases

By clicking the Sign Up button, you agree to the privacy policy

en_USEN
en_USEN es_ESES
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.